Itraconazole

證據等級: L5

預測適應症: 1 個

Itraconazole: From Fungal Infections to Pneumocystosis

One-Sentence Summary

Itraconazole is a triazole antifungal agent established for the treatment of systemic fungal infections including aspergillosis, histoplasmosis, and candidiasis. The TxGNN model predicts it may be effective for Pneumocystosis (Pneumocystis jirovecii pneumonia, PCP), with 0 clinical trials and 20 publications associated with this direction — however, mechanistic analysis reveals this high-scoring prediction (99.34%) is almost certainly a false positive driven by a structural bias in the knowledge graph, not genuine therapeutic potential.

Quick Overview

Item	Content
Original Indication	Systemic fungal infections (aspergillosis, histoplasmosis, candidiasis)
Predicted New Indication	Pneumocystosis (Pneumocystis jirovecii Pneumonia)
TxGNN Prediction Score	99.34%
Evidence Level	L4 — Mechanistic/preclinical studies; no clinical trial support
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

At first glance, the prediction seems plausible: itraconazole is an antifungal, and Pneumocystis jirovecii is classified as a fungus. However, this surface-level match conceals a fundamental biological incompatibility. Itraconazole works by inhibiting CYP51 (lanosterol 14α-demethylase), the enzyme that synthesises ergosterol — the sterol found in fungal cell membranes. Since ergosterol is absent from human cells, azole antifungals can selectively kill fungi without harming the host.

The critical issue is that P. jirovecii is highly atypical among fungi: it does not synthesise ergosterol at all. Instead, it scavenges and incorporates cholesterol directly from host tissues into its own membrane. This means itraconazole’s entire mechanism has no target to bind in P. jirovecii. A 2003 mechanistic study characterising the Pneumocystis carinii CYP51/Erg11 enzyme (PMID 12606318) confirmed that the organism carries CYP51 sequence variants identical to those found in azole-resistant fungi — consistent with intrinsic, class-wide azole insensitivity. There is no pharmacological workaround for this incompatibility.

The standard of care for PCP is trimethoprim-sulfamethoxazole (TMP-SMX), which targets dihydropteroate synthase in the folate synthesis pathway — a metabolic route P. jirovecii cannot substitute with host-derived folate. Clinical guidelines (PMID 21418688) do not include itraconazole or any azole as a treatment or prophylaxis option for PCP. The TxGNN score of 0.9934 most likely reflects the knowledge graph incorrectly generalising from “azole antifungal → treats fungal disease” without encoding the unique biology of P. jirovecii, producing a structurally plausible but clinically invalid repurposing signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The retrieved publications address opportunistic fungal infections and immunocompromised populations broadly. None document itraconazole efficacy against P. jirovecii. The most mechanistically significant paper (PMID 12606318) explains precisely why azoles fail against this organism.

PMID	Year	Type	Journal	Key Findings
11737382	2001	RCT	HIV Medicine	Phase III double-blind RCT of itraconazole capsules for prevention of deep fungal infections in HIV-positive patients; primary endpoint was broad fungal prophylaxis, not PCP specifically — no efficacy signal against P. jirovecii
21418688	2010	Review/Guideline	BMJ Clinical Evidence	HIV primary and secondary prophylaxis for opportunistic infections; confirms TMP-SMX as the only recommended agent for PCP prophylaxis — itraconazole not listed
2121456	1990	Review	Drugs	Comprehensive review of therapy and prophylaxis for systemic protozoan and fungal infections; itraconazole not indicated for Pneumocystis treatment
8397916	1993	Review	Curr Clin Topics Infect Dis	Infection prophylaxis in bone marrow transplant recipients; TMP-SMX established as standard for PCP prevention in transplant settings
8016481	1993	Review	Semin Respir Infect	Infections after lung transplantation; PCP prevention and management overview — azoles not recommended for PCP
12606318	2003	Mechanistic	Am J Respir Cell Mol Biol	Characterisation of P. carinii CYP51/Erg11 enzyme; two of 13 potential azole-resistance sites in P. carinii CYP51 are identical to confirmed azole-resistant organisms — directly explains intrinsic itraconazole insensitivity
30429396	2018	Observational	Indian J Med Microbiol	Respiratory fungal pathogen profiles comparing immunocompetent vs. immunocompromised hosts; susceptibility data underscores azole inefficacy against P. jirovecii
26036497	2015	Retrospective Cohort	Transplantation Proceedings	Invasive fungal infections after kidney transplantation; itraconazole used for non-PCP fungal infections — PCP managed separately with TMP-SMX
36891307	2023	Case Report	Frontiers in Immunology	Talaromyces marneffei and P. jirovecii co-infection in a child with STAT1 mutation; TMP-SMX used for the PCP component — itraconazole not applicable
8967681	1996	Case Report	Annals of Internal Medicine	Uveitis associated with rifabutin prophylaxis and itraconazole therapy in an HIV patient; documents itraconazole use for MAC/fungal co-prophylaxis context, not PCP

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Itraconazole’s mechanism of action — CYP51/ergosterol inhibition — has no valid target in Pneumocystis jirovecii because this organism lacks ergosterol entirely. There is zero clinical trial evidence supporting this use, and the published mechanistic literature (PMID 12606318) explicitly confirms azole insensitivity in P. jirovecii at the molecular level. The TxGNN score of 99.34% is a knowledge graph false positive, not a therapeutic signal.

To proceed, the following is needed:

No further development of itraconazole for pneumocystosis is warranted; mechanistic incompatibility is definitive and well-documented
If broader PCP treatment research is the goal, repurposing candidates should target the folate pathway (dihydropteroate synthase, DHFR), P. jirovecii β-glucan synthesis (caspofungin has shown some activity), or cell wall stress mechanisms
The TxGNN pipeline should consider implementing a post-processing exclusion rule for azole antifungal × Pneumocystis combinations, flagging them as structurally predicted false positives prior to evidence collection
Obtain official itraconazole package insert (Philippines FDA) to complete the safety data gaps (DG001) and DrugBank MOA entry (DG002) for completeness of the drug-level record, even though they do not change this recommendation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.